EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of Drug-like Inhibitors of the Human Caf1/CNOT7 poly(A)-Selective Nuclease Using Compound Screening

Ishwinder Kaur iD, Lubna Hashmi, Peter M Fischer iD, Gerlof Sebastiaan Winkler iD

Biomolecules · 2025

DOI: 10.3390/biom15111563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Ishwinder Kaur und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Biodiscovery Institute, University of Nottingham, University Park, Nottingham NG7 2RD, UK. Hauptthemen laut MEDLINE: Transcription Factors, Drug Discovery, Enzyme Inhibitors. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The human Ccr4–Not complex is a central regulator of post-transcriptional gene regulation, impacting on translation and mRNA degradation. In mRNA degradation, Ccr4–Not participates in the shortening of the mRNA poly(A)-tail via two catalytic subunits. The Caf1 nuclease is encoded by the highly similar paralogues CNOT7 or CNOT8. In addition to its poly(A)-specific ribonuclease activity, this subunit also provides a structural role by binding Ccr4, the second catalytic nuclease subunit encoded by the paralogues CNOT6 or CNOT6L. To facilitate investigations into the roles of the Caf1 subunit, and to complement genetic tools, we set out to identify inhibitors of the enzymatic activity of Caf1/CNOT7. To this end, we screened a library of 10,880 chemically diverse, drug-like compounds using a fluorescence-based biochemical assay. This effort led to the discovery of 15 inhibitors of Caf1/CNOT7 with biochemical IC50 values below 25 μM. Molecular docking was performed to explore potential binding modes of these compounds. The compounds reported here may be useful to differentiate between catalytic and non-catalytic roles of Caf1/CNOT7. In addition, they may be valuable starting points for the development of more potent inhibitors of the Caf1/CNOT7 poly(A)-selective ribonuclease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcription FactorsDrug DiscoveryEnzyme InhibitorsHumansRibonucleasesMolecular Docking SimulationSmall Molecule LibrariesExoribonucleasesRepressor Proteins

Stichwörter der Autor:innen

CNOT7CNOT8Caf1compound screeningdeadenylasegene regulationinhibitormRNAnuclease

Substanzen

CNOT7 protein, humanTranscription FactorsEnzyme InhibitorsRibonucleasesSmall Molecule LibrariesExoribonucleasesRepressor Proteins

Autor:innen und Institutionen

  • School of Pharmacy, Biodiscovery Institute, University of Nottingham, University Park, Nottingham NG7 2RD, UK.

ORCID-Profile: Ishwinder Kaur, Peter M Fischer, Gerlof Sebastiaan Winkler

Förderung

  • Medical Research Council

Zitieren

APA

Kaur, I., Hashmi, L., Fischer, P. M., & Winkler, G. S. (2025). Discovery of Drug-like Inhibitors of the Human Caf1/CNOT7 poly(A)-Selective Nuclease Using Compound Screening. Biomolecules. https://doi.org/10.3390/biom15111563

Vancouver

Kaur I, Hashmi L, Fischer PM, Winkler GS. Discovery of Drug-like Inhibitors of the Human Caf1/CNOT7 poly(A)-Selective Nuclease Using Compound Screening. Biomolecules. 2025. doi:10.3390/biom15111563

BibTeX
@article{Kaur2025,
  author = {Kaur, Ishwinder and Hashmi, Lubna and Fischer, Peter M and Winkler, Gerlof Sebastiaan},
  title = {Discovery of Drug-like Inhibitors of the Human Caf1/CNOT7 poly(A)-Selective Nuclease Using Compound Screening},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15111563}
}
Kostenlos starten →